SCHEMBL13614267

SCHEMBL13614267

COC(=O)Cc1ccc(-c2cc(OS(=O)(=O)C(F)(F)F)c3c(c2)C(C)(C)CCC3=O)cc1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.34
RXRA P19793 6/20 0.34
RXRB P28702 5/20 0.34
RXRG P48443 5/20 0.34
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
CYP26A1 O43174 4/20 0.33
CHEK1 O14757 3/20 0.33
CYP26B1 Q9NR63 1/20 0.33
CTSG P08311 1/20 0.32
CMA1 P23946 1/20 0.32
RARA P10276 1/20 0.32
RARB P10826 1/20 0.32
RARG P13631 1/20 0.32
MMP9 P14780 1/20 0.32
HNF4A P41235 1/20 0.31
DRD2 P14416 2/20 0.31
DRD3 P35462 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4520485 0.87 CYP26A1 (0.34) PDK2CYP4F2CYP4A11CYP26A1CYP26B1
SCHEMBL14525074 0.82 RXRA (0.37) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL13614264 0.80 ALDH1A1 (0.40) PDK2RXRARXRBRXRGCYP4F2
SCHEMBL13614262 0.77 RXRA (0.35) PDK2RXRARXRBRXRGCYP4F2
SCHEMBL13613955 0.76 RARG (0.38) RXRARXRBRXRGCHEK1RARA
SCHEMBL5538842 0.75 CA5A (0.47) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL5536191 0.73 RXRA (0.43) PDK2RXRARXRBRXRGCYP4F2
SCHEMBL5537348 0.72 CYP4F2 (0.43) PDK2RXRARXRBRXRGCYP4F2
SCHEMBL5538841 0.69 CYP4F2 (0.43) PDK2RXRARXRBRXRGCYP4F2
SCHEMBL6296930 0.69 CYP4F2 (0.54) PDK2CYP4F2CYP4A11MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638648-B2 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN INC. (US) 2009-12-29 US disclosed
US-20080004455-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN, INC. (US) 2008-01-03 US disclosed
US-7226951-B2 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN, INC. (US) 2007-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004455-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same CYP1A2, CYP2A7, CYP3A7 PDK2 754/4885RXRA 351/4885RXRB 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.